Furthermore, teclistamab, a BiTE targeting CD3 and BCMA, has been reported to improve disease activity in patients with autoimmune diseases, including cases of severe, refractory SLE (190). This evidence concerns the gene TNFRSF17 and systemic lupus erythematosus.